Sheryl Stevenson

The novel therapeutic for keratoconus does not require corneal epithelium removal and is slated to launch commercially in early 2026.

A new study reveals a promising drug reduces vision loss in Stargardt disease, showing significant safety and efficacy over 2 years.

Continued research shows that earlier treatment significantly enhances tissue preservation in patients with geographic atrophy, emphasizing the importance of timely intervention.

A study shows enhanced safety and efficacy in epi-on cross-linking for keratoconus, utilizing oxygen-rich boost goggles during treatment.

Dr Khanani shared his first-time results talk during an AAO specialty day

The video-driven platform will improve workflow, education and engagement, said Inder Paul Singh, MD

In-orbit imaging drives innovation in terrestrial telemedicine, the NASA scientist explained

Christine A. Curcio, PhD, shares an update on histology and its critical role in advancing <3 μm optical coherence tomography interpretation

Preliminary analysis of FLIO data using artificial intelligence suggests potential novel biomarkers

High-resolution optical coherence tomography illuminates crucial biomarkers in age-related macular degeneration, Dr Sadda said

FLIO ushers clinicians from structural to functional imaging, said Robert Sergott, MD, in a presentation at the International SPECTRALIS Symposium

At the 2025 ASCRS meeting, Dr Ang said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery

Endoscopic cyclophotocoagulation (ECP) has major potential for patients with glaucoma

Clinicians react to the US approval of revakinagene taroretcel-lwey (Encelto; Neurotech Pharmaceuticals) for macular telangiectasia type 2

The Australia-based organisation is partnering with the UN Friends of Vision group for an event on 11 March

In the group of new appointees, the organisation welcomed community members who are passionate about advocacy and education

The Elios procedure shows promise in improving aqueous humour outflow and enhancing the effectiveness of minimally invasive glaucoma surgery, with ongoing research exploring optimal treatment strategies.

Voyager DSLT is already available in select markets in the EU and the UK, and reduces the specialised training required with manual selective laser trabeculoplasty

Professor Anat Loewenstein, MD, speaks about her presentation from the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting

Alcon Laboratories is voluntarily recalling one lot (Lot 10101) of its Systane Lubricant Eye Drops Ultra PF, Single Vials On-the-Go, 25 count, after identifying fungal contamination in a sealed vial.

Research indicates suppressive valacyclovir could help patients avoid keratitis and iritis flare-ups

Vikas Chopra, MD, focused on minimally invasive glaucoma surgery (MIGS) and its significance in enhancing glaucoma treatment. He highlighted how MIGS allows ophthalmologists to perform interventions at an earlier stage and with increased safety, resulting in improved patient outcomes.

Victoria L. Tseng, MD, PhD, discusses SLT, microshunts and what glaucoma specialists can learn from large data sets

During a conversation at the American Academy of Ophthalmology annual meeting in Chicago, T.Y. Alvin Liu, MD, discussed plans for the James P. Gills Jr, MD, & Heather Gills Artificial Intelligence Innovation Center at the Wilmer Eye Institute at Johns Hopkins Medicine.

Michael Singer, MD, shared insights from on his experience using a preservative-free, chloroprocaine ophthalmic gel as anesthesia for intravitreal injections and the results of research on the effectiveness of gel versus traditional drops.

Brent Kramer, MD, presents on an alternative to IV sedation for cataract surgeries and complex cases

Nathan Radcliffe, MD, shared insights from his presentation at the annual meeting of the American Academy of Ophthalmology entitled, "Early cataract extraction for angle closure glaucoma."

Fatemeh Rajaii, MD, PhD, an associate professor at Wilmer Eye Institute, Johns Hopkins, discussed emerging therapies in thyroid eye disease (TED) from her presentation at the American Academy of Ophthalmology’s annual meeting in Chicago.

George O. Waring, IV, MD provides insights from an on-demand poster as part of the annual American Academy of Ophthalmology taking place in Chicago, Illinois. This poster shared data on the the 9-month FDA data of the recently approved excimer laser, the TENEO laser, by Bausch + Lomb.

At this year's American Academy of Ophthalmology (AAO) meeting, Jonathan Brugger, MD, spoke about the changing approach to epimacular membranes and the use of brilliant blue in the procedure.